Register Login

Abiopharma

  • Home
  • About
  • Newsroom
    • News
    • Company List
  • Events
  • Automated Tools
  • Contact

News list

PDS Biotechnology Corporation (PDSB)

  • Business News
  • Oct. 29, 2025, 12:37 UTC
  • 4
  • 0 comments

PDS Biotech to Seek Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer

Market reaction Comment Full text

Moleculin Biotech Inc. (MBRX)

  • Business News
  • Oct. 29, 2025, 12:35 UTC
  • 6
  • 0 comments

Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin

Market reaction Comment Full text

VistaGen Therapeutics Inc. (VTGN)

  • Business News
  • Oct. 29, 2025, 12:30 UTC
  • 4
  • 0 comments

Vistagen Appoints Paul Edick to its Board of Directors

Market reaction Comment Full text

Zoetis Inc. (ZTS)

  • Business News
  • Oct. 29, 2025, 12:30 UTC
  • 4
  • 0 comments

Zoetis Receives European Commission Marketing Authorization for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in Cats

Market reaction Comment Full text

ProPhase Labs Inc. (PRPH)

  • Business News
  • Oct. 29, 2025, 12:30 UTC
  • 4
  • 0 comments

ProPhase Labs Announces Publication of BE-Smart Esophageal Cancer Study in the Official Journal of the American College of Gastroenterology

Market reaction Comment Full text

PolyPid (PYPD)

  • Business News
  • Oct. 29, 2025, 12:30 UTC
  • 4
  • 0 comments

PolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025

Market reaction Comment Full text

Silo Pharma Inc (SILO)

  • Business News
  • Oct. 29, 2025, 12:25 UTC
  • 4
  • 0 comments

Silo Pharma Selects Alphaledger’s T12 Fund for Tokenized Real-World Asset Investments on Solana Blockchain

Market reaction Comment Full text

Rigel Pharmaceuticals Inc (RIGL)

  • Business News
  • Oct. 29, 2025, 12:05 UTC
  • 4
  • 0 comments

Rigel Announces Conference Call and Webcast to Report Third Quarter 2025 Financial Results and Business Update

Market reaction Comment Full text

Johnson & Johnson (JNJ)

  • Business News
  • Oct. 29, 2025, 12:05 UTC
  • 3
  • 0 comments

Johnson & Johnson announces first head-to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting

Market reaction Comment Full text

PAVmed Inc (PAVMZ)

  • Business News
  • Oct. 29, 2025, 12:01 UTC
  • 6
  • 0 comments

Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 12, 2025

Market reaction Comment Full text
  • Previous
  • 57
  • 58
  • 59
  • 60
  • 61
  • Next

Search

News categories

  • Technical Exchange News(10323)
  • Event(1482)
  • SEC News(175623)
  • FDA Approval(9648)
  • Company Report(721)
  • Business News(117818)
Market reaction

© Copyright Abiopharma. All Rights Reserved
Designed by Alexey Vershinin